The Kawasaki Disease Comparative Effectiveness Trial

A national clinical study to compare effectiveness of treatments for children with Kawasaki disease

Is your child currently in the hospital for treatment of Kawasaki disease?

  • The standard first treatment for children with Kawasaki disease is intravenous immunoglobulin (IVIG)
  • A small group of children (10% to 15%) may need additional rounds of treatment because the fever does not go away after the first treatment. This recurrent fever may happen while the child is in the hospital or after returning home.
  • If your child needs a second round of treatment, he/she may receive either intravenous immunoglobulin (IVIG) or infliximab. Only children who will need a second round of treatment are eligible for the KIDCARE study.

Why are we doing the study?

  • Although both intravenous immunoglobulin (IVIG) and infliximab are well-accepted treatments, researchers want to know if one is more effective than the other for children who have fever after the first treatment. This will help improve how care is offered to children.
  • Parents may be the best observers of their child’s signs and symptoms during and after treatment. This information is important for understanding how children experience the treatments but has never been collected before. In KIDCARE, we are engaging parents to help us collect this information about their child.
  • A study doctor or research coordinator at your hospital may contact you if your child is eligible for the study.


We hope you will help us improve care for children with Kawasaki disease

Need additional KIDCARE information? Submit your information via the contact form below and a KDF representative will contact you within a few hours.